Postoperative Pain - Pipeline Insight, 2024

This “Postoperative Pain- Pipeline Insight, 2024,” report provides comprehensive insights about 45+ companies and 50+ pipeline drugs in Postoperative Pain pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Postoperative Pain Understanding

Postoperative Pain: Overview

Postoperative or Postsurgical pain is defined as pain lasting more than 3 to 6 months after surgery. The pain differs in quality and location from pain experienced prior to surgery, and is usually associated with iatrogenic neuropathic pain caused by surgical injury to a major peripheral nerve. Although all types of surgery can lead to persistent postoperative pain (PPP), some surgeries are at higher risk of causing nerve damage, such as inguinal hernia repair, breast and thoracic surgery, leg amputation, and coronary artery bypass surgery. Consequently, surgical techniques that avoid nerve damage should be applied whenever possible. Postoperative pain can be divided into acute pain and chronic pain. Acute pain is experienced immediately after surgery (up to 7 days) and pain which lasts more than 3 months after the injury is considered to be chronic pain. Acute and chronic pain can arise from cutaneous, deep somatic or visceral structures. Surgery, by nature, involves the cutting of tissues and nerves, which induces the injury response (inflammation, hyperalgesia) and alterations of peripheral and central nervous system (CNS) pain processing (central sensitization), which can lead to chronic pain. After peripheral nerve injury, increased sodium-channel (Na) expression on sensitized primary afferent nerves leads to spontaneous activity with increased glutamate release from the nerve endings. This excess of glutamate acts on glutamate receptors (N-methyl-D-aspartate [NMDA], a-Amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid [AMPA], kainate, and metabotropic glutamate receptors [mGluRs]), thereby triggering intracellular changes. These changes contribute to sustained central sensitization, with increased spontaneous impulse discharges, reduced thresholds, increased response to peripheral stimuli, and expanded receptive fields of central neurons. Central sensitization is an amplification of pain signaling in the spinal cord from repeated stimulation from the periphery. Surgery increases synaptic activity in dorsal horn neurons. Humoral signals released from inflamed tissue act on the CNS and intracellular kinases. Within hours, altered gene transcription in the dorsal root ganglion (DRG) of sensory neurons and the spinal cord augment release of excitatory transmitters and reduce inhibitory transmitters. This results in neuronal excitability lasting days. When the noxious stimuli continue, then neuroplastic transformations occur and a positive feedback loop forms. Over time, neurons change structure, function, or chemical profile leading to pain as a disease. Effective treatment of postoperative pain includes a number of factors, including good nursing, non-pharmacological techniques, such as distraction, and balanced (multimodal) analgesia to provide adequate pain relief with optimal drug combinations used at the lowest effective doses.

Postoperative Pain- Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Postoperative Pain pipeline landscape is provided which includes the disease overview and Postoperative Pain treatment guidelines. The assessment part of the report embraces, in depth Postoperative Pain commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Postoperative Pain collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Postoperative Pain R&D. The therapies under development are focused on novel approaches to treat/improve Postoperative Pain.

Postoperative Pain Emerging Drugs Chapters

This segment of the Postoperative Pain report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Postoperative Pain Emerging Drugs

VVZ-149: Vivozon Pharmaceutical Inc.VVZ-149 is a new mechanism-based non-narcotic and non-NSAID analgesic demonstrating the robust (comparable to morphine) pain-suppressing efficacy in a panel of in vivo models (post-operative, formalin-induced or neuropathic pain model). The compound has also shown the anti-itching effect in the serotonin-induced itching model. These in vivo efficacies are attributed to the synergistic or additive dual antagonistic activity of VVZ-149 against GlyT2 and 5HT2A which are key receptors for the transmission of the pain signal in spinal dorsal horn area and/or peripheral sensory neurons. Currently the drug is in Phase III stage of Clinical trial evaluation for the treatment of Postoperative Pain.

CA-008: Concentric AnalgesicsConcentric Analgesics’ lead product candidate (CA-008) for postsurgical pain is a first-in-class prodrug therapeutic that rapidly converts to capsaicin, a potent TRPV1 agonist. Unlike local anesthetics, capsaicin selectively desensitizes pain-conducting nerve fibers without producing sensory numbness or motor weakness. Vocacapsaicin, injected into the surgical site as an aqueous solution during surgery, has the potential to reduce, and in some patients eliminate, the need for opioids in the postsurgical recovery period and provide clinically meaningful pain relief for two weeks. Vocacapsaicin has received both Fast Track Designation (2017) and Breakthrough Therapy Designation (2018) from the U.S. Food and Drug Administration. Vocacapsaicin is the company’s Phase III-ready lead product candidate for postsurgical pain. The drug is currently in Phase II stage of clinical trial evaluation to treat Postoperative Pain.

Postoperative Pain: Therapeutic Assessment

This segment of the report provides insights about the different Postoperative Pain drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Postoperative Pain

There are approx. 50+ key companies which are developing the therapies for Postoperative Pain. The companies which have their Postoperative Pain drug candidates in the most advanced stage, i.e. phase III include, Vivozon Pharmaceutical Inc.

Phases

This report covers around 50+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Postoperative Pain pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• intravenous
• Subcutaneous
• Topical.

Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Postoperative Pain: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Postoperative Pain therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Postoperative Pain drugs.

Postoperative Pain Report Insights

• Postoperative Pain Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Postoperative Pain Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Postoperative Pain drugs?
• How many Postoperative Pain drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Postoperative Pain?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Postoperative Pain therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Postoperative Pain and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Concentric Analgesics
• Oculis Pharma
• Vivozon Pharmaceutical Inc.
• Haisco Pharmaceutical Group
• Jiangsu HengRui Medicine Co., Ltd.
• Nevakar, Inc.
• Flexion Therapeutics
• LipoCure
• SiteOne Therapeutics
• Allay Therapeutics
• Bexson Biomedical
• InSitu Biologics

Key Products

• VVZ-149
• HSK21542
• OCS-01
• CA-008
• HR021618
• NVK-009
• FX 301
• LC-400
• ST-2427
• ATX-201
• BB-106
• INSB-200

This product will be delivered within 1-3 business days.